Skip to main content

#Ai and infectious disease #diagnostics: state of the art and future #perspectives

 


Summary

Artificial intelligence (AI) is reshaping infectious disease diagnostics by supporting clinical decision making, optimising laboratory and clinical workflows, and enabling real-time disease surveillance. AI approaches improve pathogen detection, antimicrobial stewardship, and treatment monitoring, enhancing diagnostic accuracy, efficiency, and scalability. The role of AI in combating antimicrobial resistance is particularly significant, enabling rapid pathogen identification and personalised treatment. Despite progress over the past two decades, widespread AI adoption in infectious disease diagnostics faces challenges. In high-income countries, fragmented data ecosystems, incomplete datasets, and algorithmic bias hinder clinical integration. Meanwhile, low-income and middle-income countries contend with limited digital infrastructure, unstandardised data, and financial constraints, exacerbating disparities in diagnostic access. Further barriers include concerns over interoperability, data privacy, cybersecurity, and the regulation of AI implementation. This paper examines the role of AI in infectious disease diagnostics, highlighting both opportunities and limitations. It underscores the need for coordinated investments in digital infrastructure, harmonised data-sharing frameworks, and clinician engagement to support equitable, sustainable adoption. Addressing these challenges will enable health-care systems to harness the potential of AI to improve infectious disease detection, prevention, and management of infectious diseases, thereby strengthening global health resilience.

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00354-8/abstract?rss=yes

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...